Brian Abrahams's Stock Ratings

RBC Capital Analyst

Brian Abrahams is an analyst at RBC Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/04/2025

Overall Average Return

-4.37%

Smart Score

53.1%

Overall Average Return Percentile

28th

Number of Ratings

487
Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

7 Analysts Have This To Say About NewAmsterdam Pharma
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
Prothena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts
Analyst Expectations For Vertex Pharmaceuticals's Future
16 Analysts Have This To Say About Gilead Sciences
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
Biogen's Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.
A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts
What Analysts Are Saying About Incyte Stock
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved